With over 3,000 employees and 25 years of experience, Sai Life Sciences collaborates with over 300 global pharma and biotech companies to advance innovative drug development.

Sai Life Sciences boasts a seasoned team of scientists with extensive experience in peptide discovery and development, enhancing their capacity to meet client needs.

Sai Life Sciences Limited has inaugurated a Peptide Research Center at its R&D Campus in Hyderabad, India, on April 3, 2025.

The center aims to assist pharmaceutical and biotech companies with specialized services in peptide synthesis, discovery, and advanced modalities like complex conjugates.

By integrating advanced technologies such as automation and robotics, the center seeks to improve efficiency and precision in the development of peptide-based therapeutics.

The center aims to enhance the company's capabilities in peptide synthesis and conjugation in response to the growing demand for peptide-based therapeutics.

This new facility will complement Sai Life Sciences' comprehensive discovery services, which include synthetic and medicinal chemistry, biology, DMPK, and toxicology.

This holistic approach is designed to accelerate drug development timelines and improve success rates for peptide therapies.

Maneesh Pingle, Head of Discovery Services, highlighted the rapid rise in demand for peptide therapeutics due to their high specificity and biocompatibility.

CEO Krishna Kanumuri emphasized the importance of this investment for staying ahead in the pharmaceutical industry's shift towards complex modalities like peptides.

The Peptide Research Center is equipped with advanced automation, liquid handling, robotics, and high-throughput systems to enhance precision and efficiency.

By integrating these capabilities, Sai Life Sciences is positioned to facilitate seamless drug discovery processes.